Product category:
Clinical chemistry analysis
News Release from: Medical Solutions
Edited by the Laboratorytalk Editorial
Team on 28 August 2003
LBC screening deal
Provider of private cervical screening services to use LBC screening technology from cancer and pathology services group
Medical Solutions, a cancer and pathology services group, reports that Doctors Laboratory, a provider of private cervical screening in the UK, is adopting Medical Solutions's SurePath for their LBC screening SurePath system will be supplied by Medical Solutions in the UK under licence from TriPath Imaging
This article was originally published on Laboratorytalk on 24 Mar 2004 at 8.00am (UK)
Related stories
Pathology services for NHS Trust
Swindon and Marlborough NHS Trust finds necessary pathology expertise through remote locum service
Double anniversary at Focus
Supplier of one quarter of the world's haematology analysers celebrates its twentieth birthday, while its parent company celebrates its fiftieth
Merger of HTP operations
"With a combined instrumentation and biochemistry team we can respond faster and more flexibly to the assaying demands of current and future customers"
SurePath has recently demonstrated to the Food and Drug Administration a 64.4% improvement in detection of high-grade lesions compared to conventional smear screening.
The SurePath screening process uses a high throughput PrepStain robot to produce slides, which are highly consistent and very clear to read so there is never any need to reprocess specimens to remove excess red cells.
SurePath also provides a unique collection system whereby the brush head is transferred to the collection vial, thus ensuring 100% of the sample cells from the cervix are retained and are sent to the laboratory for examination and so eliminating the need for another smear sample to be taken.
Charles Green, chief executive of Medical Solutions, said: "This decision by Doctors Laboratory, which is, by far, the largest provider of private cervical screening in the UK, is a great endorsement for the SurePath system.
"We now eagerly await the Nice (the National Institute of Clinical Excellence) report issuing its final guidance to the NHS, after its preliminary report recommended the use of liquid based cytology within the NHS.
"This report is expected in September".
• Medical Solutions: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
